Lexaria Bioscience (LEXX) Cash from Investing Activities (2010 - 2026)
Lexaria Bioscience's (LEXX) quarterly Cash from Investing Activities came in at -$53909.0 in Q1 2026, down 93.26% year-on-year from -$800286.1 in Q1 2025, and down 957.25% quarter-over-quarter from -$5099.0 in Q4 2025.
Lexaria Bioscience (LEXX) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Lexaria Bioscience has disclosed Cash from Investing Activities across 17 years of filings, most recently posting -$53909.0 for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$53909.0, down 93.26% year-over-year; the trailing twelve-month figure through Feb 2026 was -$236329.0 (down 50.25% YoY), and the FY2025 annual result was -$243019.0, down 28.85% from the prior year.
- Cash from Investing Activities came in at -$53909.0 for Q1 2026 at Lexaria Bioscience, down from -$5099.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$5099.0 in Q4 2025 to a low of -$157878.0 in Q3 2025.
- The 5-year median for Cash from Investing Activities is -$37804.0 (2024), against an average of -$46039.2.
- Across the five-year window, Cash from Investing Activities plunged 2502150.0% in 2022 and soared 86.51% in 2025, its largest moves.
- Lexaria Bioscience's Cash from Investing Activities stood at -$34842.0 in 2022, then decreased by 14.88% to -$40026.0 in 2023, then increased by 5.55% to -$37804.0 in 2024, then jumped by 86.51% to -$5099.0 in 2025, then plunged by 957.25% to -$53909.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$53909.0 (Q1 2026), -$5099.0 (Q4 2025), and -$157878.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | Lexaria Bioscience | 7.49 Mn | 1.97 Mn | 20,000.00 | -53,909.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -53,909.00 |
| Feb 28, 2026 | -53,909.00 |
| Nov 30, 2025 | -5,099.00 |
| Nov 30, 2025 | -5,099.00 |
| Aug 31, 2025 | -157,878.00 |
| Aug 31, 2025 | -157,878.00 |
| May 31, 2025 | -19,443.00 |
| May 31, 2025 | -19,443.00 |
| Feb 28, 2025 | -27,894.00 |
| Feb 28, 2025 | -27,894.00 |
| Nov 30, 2024 | -37,804.00 |
| Nov 30, 2024 | -37,804.00 |
| Aug 31, 2024 | -69,587.00 |
| Aug 31, 2024 | -69,587.00 |
| May 31, 2024 | -22,002.00 |
| May 31, 2024 | -22,002.00 |
| Feb 29, 2024 | -56,990.00 |
| Feb 29, 2024 | -56,990.00 |
| Nov 30, 2023 | -40,026.00 |
| Nov 30, 2023 | -40,026.00 |